References
- Jakubczyc A, Neurohr C. Diagnostik und therapie bei interstitiellen lungenerkrankungen. Deutsche Medizinische Wochenschrift. 2018;143(24): 1774–1777. doi:10.1055/a-0622-9299.
- Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). The New England Journal of Medicine. 1984;310(3): 154–166. doi:10.1056/NEJM198401193100304.
- Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respiratory Research. 2020;21(1): 32. doi:10.1186/s12931-020-1296-3.
- Olson AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and inter-stitial lung diseases at risk of a progressive-fibrosing pheno-type. European Respiratory Review. 2018;27(150): 180077. doi:10.1183/16000617.0077-2018.
- Borie R, Le Guen P, Ghanem M, Taillé C, Dupin C, Dieudé P, et al. The genetics of interstitial lung diseases. European Respiratory Review. 2019;28(153): 190053. doi:10.1183/16000617.0053-2019.
- Montesi SB, Fisher JH, Martinez FJ, Selman M, Pardo A, Johannson KA. Update in interstitial lung disease 2019. American Journal of Respiratory and Critical Care Medicine. 2020;202(4): 500–507. doi:10.1164/rccm.202002-0360UP.
- Demedts M, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, et al. Interstitial lung diseases: an epidemiological overview. The European Respiratory Journal Supplement. 2001;32: 2s–16s.
- Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. American Journal of Respiratory and Critical Care Medicine. 2013;188(8): e13–e64. doi:10.1164/rccm.201309-1634ST.
- Paciolla M, Pescatore A, Conte MI, Esposito E, Incoronato M, Lioi MB, et al. Rare mendelian primary immunodeficiency diseases associated to impaired NF-κB signaling. Genes and Immunity. 2015;16(4): 239–246. doi:10.1038/gene.2015.3.
- Saitoh Y, Martínez Bruyn VJ, Uota S, Hasegawa A, Yamamoto N, Imoto I, et al. Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells. Lung Cancer. 2010;70(3): 263–270. doi:10.1016/j.lungcan.2010.03.001.
- Meyer KC, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? The European Respiratory Journal. 2011;38(4): 761–769. doi:10.1183/09031936.00069509.
- van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodula-tory treatment of interstitial lung disease. Therapeutic Advances in Respiratory Disease. 2022;16: 17534666221117002. doi:10.1177/17534666221117002.
- Meyer KC. Immunosuppressive agents and interstitial lung disease: what are the risks? Expert Review of Respiratory Medicine. 2014;8(3): 263–266. doi:10.1586/17476348.2014.880054.
- Kapnadak SG, Raghu G. Lung transplantation for interstitial lung disease. European Respiratory Review. 2021;30(161): 210017. doi:10.1183/16000617.0017-2021.
- Stącel T, Nęcki M, Antończyk R, Latos M, Urlik M, Kościołek J, et al. Effectiveness of lung transplantation in patients with inter-stitial lung diseases. Transplantation Proceedings. 2020;52(7): 2143–2148. doi:10.1016/j.transproceed.2020.03.050.
- Mathai SK, Schwartz DA, Warg LA. Genetic susceptibility and pulmonary fibrosis. Current Opinion in Pulmonary Medicine. 2014;20(5): 429–435. doi:10.1097/MCP.0000000000000074.
- Kropski JA. Familial interstitial lung disease. Seminars in Respiratory and Critical Care Medicine. 2020;41(2): 229–237. doi:10.1055/s-0040-1708054.
- Mikolasch TA, Garthwaite HS, Porter JC. Update in diagnosis and management of interstitial lung disease. Clinical Medicine (London, England). 2017;17(2): 146–153. doi:10.7861/clinmedicine.17-2-146.
- Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. European Respiratory Review. 2019;28(151): 180100. doi:10.1183/16000617.0100-2018.